Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

Chemotherapy in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia
A Phase II Study of Alternating Cycles of Fludarabine and Cyclophosphamide in Previously Untreated Patients With B-cell CLL
Status: Enrolling
Updated:  7/7/2015
CCOP - Missouri Valley Cancer Consortium
mi
from
Omaha, NE
Chemotherapy in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia
A Phase II Study of Alternating Cycles of Fludarabine and Cyclophosphamide in Previously Untreated Patients With B-cell CLL
Status: Enrolling
Updated: 7/7/2015
CCOP - Missouri Valley Cancer Consortium
mi
from
Omaha, NE
Click here to add this to my saved trials
Chemotherapy in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia
A Phase II Study of Alternating Cycles of Fludarabine and Cyclophosphamide in Previously Untreated Patients With B-cell CLL
Status: Enrolling
Updated:  7/7/2015
Quain & Ramstad Clinic, P.C.
mi
from
Bismarck, ND
Chemotherapy in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia
A Phase II Study of Alternating Cycles of Fludarabine and Cyclophosphamide in Previously Untreated Patients With B-cell CLL
Status: Enrolling
Updated: 7/7/2015
Quain & Ramstad Clinic, P.C.
mi
from
Bismarck, ND
Click here to add this to my saved trials
Chemotherapy in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia
A Phase II Study of Alternating Cycles of Fludarabine and Cyclophosphamide in Previously Untreated Patients With B-cell CLL
Status: Enrolling
Updated:  7/7/2015
Altru Health Systems
mi
from
Grand Forks, ND
Chemotherapy in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia
A Phase II Study of Alternating Cycles of Fludarabine and Cyclophosphamide in Previously Untreated Patients With B-cell CLL
Status: Enrolling
Updated: 7/7/2015
Altru Health Systems
mi
from
Grand Forks, ND
Click here to add this to my saved trials
Chemotherapy in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia
A Phase II Study of Alternating Cycles of Fludarabine and Cyclophosphamide in Previously Untreated Patients With B-cell CLL
Status: Enrolling
Updated:  7/7/2015
Rapid City Regional Hospital
mi
from
Rapid City, SD
Chemotherapy in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia
A Phase II Study of Alternating Cycles of Fludarabine and Cyclophosphamide in Previously Untreated Patients With B-cell CLL
Status: Enrolling
Updated: 7/7/2015
Rapid City Regional Hospital
mi
from
Rapid City, SD
Click here to add this to my saved trials
Chemotherapy in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia
A Phase II Study of Alternating Cycles of Fludarabine and Cyclophosphamide in Previously Untreated Patients With B-cell CLL
Status: Enrolling
Updated:  7/7/2015
CCOP - Sioux Community Cancer Consortium
mi
from
Sioux Falls, SD
Chemotherapy in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia
A Phase II Study of Alternating Cycles of Fludarabine and Cyclophosphamide in Previously Untreated Patients With B-cell CLL
Status: Enrolling
Updated: 7/7/2015
CCOP - Sioux Community Cancer Consortium
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
CCOP - Mayo Clinic Scottsdale Oncology Program
mi
from
Scottsdale, AZ
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
CCOP - Mayo Clinic Scottsdale Oncology Program
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
Mayo Clinic
mi
from
Jacksonville, FL
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
Mayo Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
CCOP - Illinois Oncology Research Association
mi
from
Peoria, IL
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
CCOP - Illinois Oncology Research Association
mi
from
Peoria, IL
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
CCOP - Carle Cancer Center
mi
from
Urbana, IL
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
CCOP - Carle Cancer Center
mi
from
Urbana, IL
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
CCOP - Iowa Oncology Research Association
mi
from
Des Moines, IA
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
CCOP - Iowa Oncology Research Association
mi
from
Des Moines, IA
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
Siouxland Hematology-Oncology
mi
from
Sioux City, IA
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
Siouxland Hematology-Oncology
mi
from
Sioux City, IA
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
CCOP - Wichita
mi
from
Wichita, KA
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
CCOP - Wichita
mi
from
Wichita, KA
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
CCOP - Michigan Cancer Research Consortium
mi
from
Ann Arbor, MI
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
CCOP - Michigan Cancer Research Consortium
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
CCOP - Duluth
mi
from
Duluth, MN
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
CCOP - Duluth
mi
from
Duluth, MN
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
CCOP - Missouri Valley Cancer Consortium
mi
from
Omaha, NE
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
CCOP - Missouri Valley Cancer Consortium
mi
from
Omaha, NE
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
CCOP - Merit Care Hospital
mi
from
Fargo, ND
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
CCOP - Merit Care Hospital
mi
from
Fargo, ND
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
Altru Cancer Center
mi
from
Grand Forks, ND
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
Altru Cancer Center
mi
from
Grand Forks, ND
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
CCOP - Toledo Community Hospital
mi
from
Toledo, OH
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
CCOP - Toledo Community Hospital
mi
from
Toledo, OH
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
CCOP - Oklahoma
mi
from
Tulsa, OK
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
CCOP - Oklahoma
mi
from
Tulsa, OK
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
CCOP - Geisinger Clinic and Medical Center
mi
from
Danville, PA
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
CCOP - Geisinger Clinic and Medical Center
mi
from
Danville, PA
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
Rapid City Regional Hospital
mi
from
Rapid City, SD
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
Rapid City Regional Hospital
mi
from
Rapid City, SD
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
CCOP - Sioux Community Cancer Consortium
mi
from
Sioux Falls, SD
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
CCOP - Sioux Community Cancer Consortium
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
A Phase II Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
Status: Enrolling
Updated:  7/7/2015
James Berenson, MD, Inc
mi
from
West Hollywood, CA
Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
A Phase II Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
Status: Enrolling
Updated: 7/7/2015
James Berenson, MD, Inc
mi
from
West Hollywood, CA
Click here to add this to my saved trials
Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
A Phase II Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
Status: Enrolling
Updated:  7/7/2015
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
A Phase II Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
Status: Enrolling
Updated: 7/7/2015
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
A Phase II Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
Status: Enrolling
Updated:  7/7/2015
Northwestern University
mi
from
Chicago, IL
Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
A Phase II Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
Status: Enrolling
Updated: 7/7/2015
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
A Phase II Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
Status: Enrolling
Updated:  7/7/2015
Research Facility
mi
from
New York, NY
Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
A Phase II Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
Status: Enrolling
Updated: 7/7/2015
Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
A Phase II Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
Status: Enrolling
Updated:  7/7/2015
Rigshospitalet
mi
from
Copenhagen,
Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
A Phase II Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
Status: Enrolling
Updated: 7/7/2015
Rigshospitalet
mi
from
Copenhagen,
Click here to add this to my saved trials
A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma
A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma
Status: Enrolling
Updated:  7/7/2015
Oncotherapeutics
mi
from
West Hollywood, CA
A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma
A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma
Status: Enrolling
Updated: 7/7/2015
Oncotherapeutics
mi
from
West Hollywood, CA
Click here to add this to my saved trials
A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma
A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma
Status: Enrolling
Updated:  7/7/2015
Center for Cancer & Blood Disorders
mi
from
Bethesda, MD
A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma
A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma
Status: Enrolling
Updated: 7/7/2015
Center for Cancer & Blood Disorders
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma
A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma
Status: Enrolling
Updated:  7/7/2015
Baylor University Medical Center
mi
from
Dallas, TX
A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma
A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma
Status: Enrolling
Updated: 7/7/2015
Baylor University Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance
Cross-Sectional Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance
Status: Enrolling
Updated:  7/7/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance
Cross-Sectional Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance
Status: Enrolling
Updated: 7/7/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated:  7/9/2015
UCLA's Jonsson Comprehensive Cancer Center
mi
from
Los Angeles, CA
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated: 7/9/2015
UCLA's Jonsson Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated:  7/9/2015
Children's Hospital of Orange County
mi
from
Orange, CA
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated: 7/9/2015
Children's Hospital of Orange County
mi
from
Orange, CA
Click here to add this to my saved trials
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated:  7/9/2015
The Children's Hospital, B115, University of Colorado Health Sciences Center
mi
from
Aurora, CO
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated: 7/9/2015
The Children's Hospital, B115, University of Colorado Health Sciences Center
mi
from
Aurora, CO
Click here to add this to my saved trials
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated:  7/9/2015
Northwestern University School of Medicine, Stem Cell Transplant Program, Children's Memorial Hospital
mi
from
Chicago, IL
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated: 7/9/2015
Northwestern University School of Medicine, Stem Cell Transplant Program, Children's Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated:  7/9/2015
Cardinal Bernardin Cancer Center, Loyola University Stritch School of Medicine
mi
from
Maywood, IL
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated: 7/9/2015
Cardinal Bernardin Cancer Center, Loyola University Stritch School of Medicine
mi
from
Maywood, IL
Click here to add this to my saved trials
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated:  7/9/2015
The Cancer Center, Hackensack University Medical Center
mi
from
Hackensack, NJ
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated: 7/9/2015
The Cancer Center, Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated:  7/9/2015
Cornell University, Joan & Sanford I. Weill Medical College
mi
from
New York, NY
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated: 7/9/2015
Cornell University, Joan & Sanford I. Weill Medical College
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated:  7/9/2015
Steven and Alexandra Cohen Children's Medical Center of New York
mi
from
New York, NY
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated: 7/9/2015
Steven and Alexandra Cohen Children's Medical Center of New York
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated:  7/9/2015
Mount Sinai Medical Center
mi
from
One Gustave L Levy Place, BOX 1410, New York, NY
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated: 7/9/2015
Mount Sinai Medical Center
mi
from
One Gustave L Levy Place, BOX 1410, New York, NY
Click here to add this to my saved trials
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated:  7/9/2015
Case Western Reserve Univ
mi
from
Cleveland, OH
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated: 7/9/2015
Case Western Reserve Univ
mi
from
Cleveland, OH
Click here to add this to my saved trials
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated:  7/9/2015
Western Pennsylvania Hospital
mi
from
Pittsburgh, PA
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated: 7/9/2015
Western Pennsylvania Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated:  7/9/2015
University of Pittsburgh Cancer Institute/UPMC Cancer Centers
mi
from
Pittsburgh, PA
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated: 7/9/2015
University of Pittsburgh Cancer Institute/UPMC Cancer Centers
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated:  7/9/2015
Texas Transplant Institute
mi
from
San Antonio, TX
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated: 7/9/2015
Texas Transplant Institute
mi
from
San Antonio, TX
Click here to add this to my saved trials
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated:  7/9/2015
University of Virginia, Hematopoietic Stem Cell Transplant Program
mi
from
West Complex 1300 Jefferson Park Av, Charlottesville, VA
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated: 7/9/2015
University of Virginia, Hematopoietic Stem Cell Transplant Program
mi
from
West Complex 1300 Jefferson Park Av, Charlottesville, VA
Click here to add this to my saved trials
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated:  7/9/2015
Medical College of Wisconsin - Division of Neoplastic Diseases and Related Disorders
mi
from
Milwaukee, WI
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated: 7/9/2015
Medical College of Wisconsin - Division of Neoplastic Diseases and Related Disorders
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated:  7/9/2015
Medical College of Wisconsin Pediatric Blood and Marrow Transplant Program
mi
from
Milwaukee, WI
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated: 7/9/2015
Medical College of Wisconsin Pediatric Blood and Marrow Transplant Program
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated:  7/9/2015
Szent Laszlo & Szent Istvan Hospital
mi
from
Budapest,
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated: 7/9/2015
Szent Laszlo & Szent Istvan Hospital
mi
from
Budapest,
Click here to add this to my saved trials
Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
A Phase 1 Study of Temsirolimus in Combination With Intensive Re-induction Therapy for Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma
Status: Enrolling
Updated:  7/9/2015
Children's Hospital of Alabama
mi
from
Birmingham, AL
Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
A Phase 1 Study of Temsirolimus in Combination With Intensive Re-induction Therapy for Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma
Status: Enrolling
Updated: 7/9/2015
Children's Hospital of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials